Business Context and Reporting Period
Company: Gartner Group, Inc. (Gartner)
Reporting Period: Fiscal Year Ended September 30, 1999
Business Overview: Gartner is the world's leading independent provider of research and analysis on the computer hardware, software, communications, and related IT industries. The Company operates through three segments: Research (subscription-based analysis), Services (consulting and measurement), and Events (symposia and conferences). As of September 30, 1999, the Company employed 3,402 persons and served over 9,600 client organizations.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow figures for the fiscal year are incorporated by reference to the 1999 Annual Report to Stockholders and are not explicitly stated in the provided text.
- Market Capitalization: Approximately $717.0 million (aggregate market value of voting stock held by non-affiliates as of November 30, 1999).
- Share Count: 53,674,606 shares of Class A and 34,174,116 shares of Class B outstanding as of November 30, 1999.
- Allowance for Doubtful Accounts: Ended the year at $4,938,000 (in thousands).
- Debt Facility: The Company maintains a $500 million credit facility.
Material Changes and Corporate Actions
The fiscal year was defined by a major corporate restructuring involving the separation from IMS Health.
- Recapitalization and Spin-off: On July 16, 1999, stockholders approved a recapitalization separating Gartner from IMS Health. This involved splitting common stock into Class A and Class B and distributing Class B shares to IMS Health stockholders.
- Special Dividend: A nonrecurring cash dividend of $1.1945 per share (totaling approximately $125.0 million) was paid on July 22, 1999, funded from existing cash.
- Share Repurchase: The Company conducted a Dutch Auction tender offer, repurchasing 15,759,279 shares (Class A and B) at prices between $21.00 and $24.00 per share. This was funded in part by term borrowings under the credit facility.
- Future Repurchase Obligation: The Company is required to purchase an additional 5,166,691 shares in the open market by July 2001 as part of the recapitalization plan.
- Board Structure: The Board of Directors was restructured into a classified board with three classes and staggered three-year terms.
Guidance, Outlook, and Risks
Strategic Imperatives: Management focuses on delivering cutting-edge thought leadership, dramatically growing the consultative business, and enhancing web-delivery capabilities (moving to a third-generation web platform).
Risks and Contingencies:
- Competition: The Company faces competition from independent providers, internal client organizations, and indirect competitors (media and consulting firms) with greater financial resources. Low barriers to entry exist.
- Personnel: Success depends heavily on retaining senior leadership and analysts. Intense competition for talent exists against IT producers and financial services firms.
- Tax Indemnity: Gartner must indemnify IMS Health for additional taxes if the spin-off becomes taxable due to Gartner's actions (e.g., substantial acquisitions or excessive stock option issuance) within two years. Management believes significant costs are unlikely.
- Legal Proceedings: The Company is involved in ordinary course litigation, which is not expected to have a material effect on financial position.
Investor Verification Checklist
- Verify the specific revenue, net income, and operating margin figures in the "Selected Consolidated Financial Data" (incorporated by reference from the Annual Report).
- Confirm the impact of the $125.0 million special dividend and share repurchases on the Company's liquidity and cash flow position.
- Review the details of the $500 million credit facility and the specific terms of the term borrowings used for the tender offer.
- Monitor compliance with the recapitalization agreement restrictions regarding stock options and acquisitions to avoid tax indemnity liabilities to IMS Health.
- Assess the progress of the "web-delivery" strategy and the growth rate of the Services segment relative to the core Research business.